PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to anti-HER2 and endocrine therapy, following induction chemotherapy, could delay disease progression in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer. Results showed a median progression-free survival (PFS) of 44.3 months in the palbociclib arm, compared with 29.1 months in the control arm.
“These results show that adding palbociclib, a well-tolerated, oral agent, to our standard treatment regimen provides a substantial and meaningful prolongation of response time and disease control for these patients who suffer from a…